pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Abbott Laboratories, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.3 across the same-window beat baseline.
Coverage balanceBalanced directional read. Positive and negative coverage are within 0 percentage points.
50% positive
50% negative
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about UBS
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention Abbott Laboratories, the most common co-covered peer. Source depth averages 2 original sources per story, versus 4.3 across the same-window beat baseline. Across a 129-day span, the pace is roughly 0.1 stories per week. The 7.5 average consequence score is above the beat benchmark of 6.5 in the same window. We currently track 2 Biotech stories that mention UBS, published between March 19, 2026 and July 25, 2026.
Stories tracked
2
Per week
0.1
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 254 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering UBS. Shared-story counts are live from our verified record — not editorial picks.
Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors. With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
UBS is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
